Press release
Global Histone Deacetylase Inhibitors Market, by Type & Application 2019
Histone deacetylase (HDAC) are enzymes which remove acetyl groups from an N-acetyl lysine amino acid present on a histone, thus wrapping the DNA tightly by the histones. Histone deacetylase inhibitors (HDIs) are compounds which interfere with this function of histone deacetylase. HDIs display promising potential in oncology for applications such as diagnosis, cancer detection and prognosis. HDIs are emerging class of oncology therapeutics for the treatment of solid and hematological malignancies. Based on the classes, histone deacetylase are classified into class 1, class 2 and class 3 HDAC. HDAC inhibitors leads to accumulation of acetylated nuclear histones in both tumor and normal tissues, providing an alternate marker for the biological activity of HDAC inhibitors. Inhibition of HDAC also results in acetylation transcription factors such as GATA-1, p53 and estrogen receptor-alpha. HDIs are potent anti-proliferative agents with moderately little effect on normal tissues.Get Sample Research Report: http://bit.ly/2ijrcHQ
Based on applications, histone deacetylase inhibitors are categorized into oncology, neurology and others diseases. Presently there are four approved HDI products in the market namely Vorinostat (Zolinza), Romidepsin (Istodax), Vidaza and Dacogen. Consequently, global biopharmaceutical companies are conducting research for its application in different indications.
North America leads the histone deacetylase inhibitors market with rapid acceptance of these products in this region. Globally, this market would be growing at a very rapid pace owing to a tremendous potential of this class of drugs in oncology therapy. Rising incidence of oncology and aging population would be the driving factors for this market.
Some of the key players in this market include Merck & Co., Inc., Celgene Corporation, Eisai Pharmaceuticals, Novartis, Acetylon Pharmaceuticals, Celleron Therapeutics, Envivo Pharmaceuticals and Pfizer, Inc. These companies are aiming to discover new products in this class, through prospective pipeline, collaborations and ventures.
Browse Full Research Report on Histone Histone Deacetylase Inhibitors Market:
http://www.transparencymarketresearch.com/histone-deacetylase-inhibitors.html
About Us
Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. We have an experienced team of Analysts, Researchers, and Consultants, who us e proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.
Contact
Transparency Market Research
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com
Browse market research blog:
https://tmrresearch.blogspot.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Global Histone Deacetylase Inhibitors Market, by Type & Application 2019 here
News-ID: 407578 • Views: …
More Releases from TMR - Research Reports

Pulmonary Drugs Market is Expected to Reach US$ 28,082.1 Million by the End of 2 …
According to the research report, the global pulmonary drugs market is expected to be worth US$ 28,082.1 mn by the end of 2024 as compared to US$ 48,039.7 mn in 2015. Analysts calculate that the global market will plummet at a CAGR of -6.3% during the forecast period of 2016 and 2024. The market will thrive as the demand for combination drugs is anticipated to remain on the rise during…

North America Ventricular Assist Device Market is rising to a valuation of US$ 1 …
According to TMR, the opportunity in the North America market for VADs, which stood at US$0.4 bn in 2015, is likely to expand at a healthy CAGR of 9.20% between 2016 and 2024 and increase to US$1.07 bn by the end of the forecast period. The destination therapy (DT) segment has been reporting a greater application of VADs than the other two indication segments. It is expected to remain the…

Dental Membrane and Bone Graft Substitutes Market to rise to US$ 922.6 Million b …
Transparency Market Research notes that innovation and expansion into emerging regions have served these companies well in strengthening their hold in the dental membrane and bone graft substitutes market. For instance, Switzerland-based Geistlich Pharma AG - a global manufacturer and supplier of dental products and devices - expanded its operations in Sydney, Australia and New Delhi, India in 2016.
The global dental membrane and bone graft substitutes market is expected to…

Human Vaccines Market is Estimated to Reach US$ 72.5 Billion by 2024
The global human vaccines market was valued at US$28.3 bn in 2015 and is estimated to reach US$72.5 bn by 2024, registering an 11.2% CAGR during the forecast period.
By age group, pediatric vaccines accounted for a 57.5% share in the global human vaccines market in 2015. Adult vaccines, on the other hand, are expected to expand at a 13.2% CAGR from 2016 to 2024. Based on product, the pneumococcal segment…
More Releases for Histone
Histone Deacetylase (HDAC) Inhibitors Market 2022 | Detailed Report
The Histone Deacetylase (HDAC) Inhibitors research report undoubtedly meets the strategic and specific needs of the businesses and companies. The report acts as a perfect window that provides an explanation of market classification, market definition, applications, market trends, and engagement. The competitive landscape is studied here in terms of product range, strategies, and prospects of the market's key players. Furthermore, the report offers insightful market data and information about the…
Histone Deacetylase 8 (Histone Deacetylase Like 1 or HDAC8 or EC 3.5.1.98) Marke …
The Histone Deacetylase 8 (Histone Deacetylase Like 1 or HDAC8 or EC 3.5.1.98) Market report offers an in-depth assessment of market dynamics, the competitive landscape, segments, and regions in order to help readers to become familiar with the Histone Deacetylase 8 (Histone Deacetylase Like 1 or HDAC8 or EC 3.5.1.98) market. It particularly sheds light on market fluctuations, pricing structure, uncertainties, potential risks, and growth prospects to help players to…
Global Histone Deacetylase Inhibitors Market Research Report
This report studies the global Histone Deacetylase Inhibitors market status and forecast, categorizes the global Histone Deacetylase Inhibitors market size (value & volume) by manufacturers, type, application, and region. This report focuses on the top manufacturers in North America, Europe, Japan, China, and other regions (India, Southeast Asia). The major manufacturers covered in this report 4SC AG Acetylon Pharmaceuticals Celleron Therapeutics Chroma Therapeutics CrystalGenomics Curis MEI Pharma Mirati Therapeutics Novartis…
Histone Deacetylase Inhibitors Market & Pipeline Insight2015
Histone Deacetylase (HDAC) are enzymes responsible for removal of acetyl groups present on acetyl lysine amino acid attached to histone. They are responsible for gene expression and regulation which is responsible for cellular functioning. It also helps in wrapping of histone over the Deoxyribonucleic acid (DNA). They are involved in cell growth and death which is responsible for maintaining steady state. Their involvement in diseases has been noted by investigators…
Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98) - Pipeline …
The latest report Histone Deacetylase 4 - Pipeline Review, H1 2017, outlays comprehensive information on the Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviewsalso reviews key players involved in Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98) targeted therapeutics development…
Global Histone Deacetylase Inhibitors Market
Histone deacetylase (HDAC) is enzymes, which inhibits histone deacetylase by removing scetyl group from n-acetyl lysine amino acid. Histone deacetylase inhibitors are emerging as potential application in diagnosis, treatment and prognosis of cancer. It is also considered as a treatment option for hematological malignancies and plays important role in epigenetic or non-epigenetic regulation. The histone deacetylase inhibitors accumulates acetylated nuclear histone in tumors and normal tissues. Thus, the inhabitation results…